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Commentary on ‘Development of Off-the-shelf Stent Grafts for Juxtarenal
Abdominal Aortic Aneurysms’
D.J. Adama,*, E.L.G. Verhoeven b
aUniversity Department of Vascular Surgery, Heart of England NHS Foundation Trust, Birmingham B9 5SS, Birmingham, UK
bDepartment of Vascular and Endovascular Surgery, Klinikum Nurnberg, Nurnberg, GermanyThe paper in this month’s journal from Resch, Haulon and
colleagues describes the ﬁrst clinical experience using a pre-loaded
fenestrated aortic stent-graft with pivot renal fenestrations in
patientswithcomplexabdominalaorticaneurysms (AAA).Regulatory
issues required the endografts to be customised, but the paper clearly
demonstrates the feasibility of CookMedical’s (Bloomington, Indiana)
proposed ‘off-the-shelf’ fenestrated device. From a technical
perspective, there are potential beneﬁts associated with the novel
pre-loadedpivot renal fenestrations. For example, in angulatednecks,
alignment of the fenestrations with the renal arteries may not be so
crucial, the pivot fenestrationsbehaving like short cuffs andgiving the
clinician some room to manoeuvre. Unlike Cook’s device which has
three fenestrations for the superior mesenteric artery and both renal
arteries, Endologix (Irvine, California) has developed an ‘off-the-shelf’
fenestrated device with two renal fenestrations and a scallop for the
visceral vessels. While bothmanufacturers claim that the majority of
short-necked and juxtarenal AAA can be treated using their graft, the
triple fenestrated platform should be more versatile and allow the
treatment of some suprarenal aneurysms as well. Specialist aortic
units will likely have access to both double and triple fenestrated
platforms allowing the treatment to be tailored to the patient and the
aneurysm, thereby avoiding the unnecessary implantation of
a complex endograft where a simpler device will sufﬁce.DOI of original article: 10.1016/j.ejvs.2012.01.022.
* Corresponding author.
E-mail address: Donald.Adam@heartofengland.nhs.uk (D.J. Adam).
1078-5884/$ e see front matter  2012 European Society for Vascular Surgery. Publishe
doi:10.1016/j.ejvs.2012.03.012The principal limitations to fenestrated endografting have been
the time for manufacture, and device costs. These limitations have
stimulated interest in chimney grafts and surgeon-modiﬁed
fenestrated devices. These other approaches may lose some of
their popularity provided the costs of the ‘off-the-shelf’ devices
reﬂect the current economic climate.
An important issue is how this technology should be dissemi-
nated to ensure the best possible patient outcomes. It is accepted
that a) patients with aortic disease should be offered all the ther-
apeutic options by a multidisciplinary team of specialists, and b)
high-volume vascular units deliver better outcomes. Such high
volume providers will have the necessary workload to become
proﬁcient with these devices in a relatively short period of time,
and thus deliver the best possible outcomes for patients. The device
manufacturers can make recommendations about the number of
cases a centre should performwith a mentor before ‘going solo’ but
theywill ﬁnd it very difﬁcult to decline to sell a device once it is CE-
marked. The ‘off-the-shelf’ technology has been keenly awaited by
the vascular community and so it is likely that everyone will want
to use it. Commissioners of healthcare, national vascular societies
and industry would do well to give this careful consideration;
otherwise the technology might fail to deliver its full potential in
terms of beneﬁt to patients.d by Elsevier Ltd. All rights reserved.
